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ABSTRACT Methamphetamine (METH), leading to striatal dopamine (DA) nerve
terminal toxicity in mammals, is also thought to induce apoptosis of striatal neurons
in rodents. We investigated the acute effects induced by multiple injections of METH
(4 3 5 mg/kg, i.p.) at 2-h intervals or a single injection of METH (20 mg/kg, i.p.) on
terminal dopaminergic toxicity markers, including DA levels, DA turnover, and tyro-
sine hydroxylase (TH) immunoreactivity in rat caudate-putamen (CPu). We further
investigated whether both treatment paradigms would change Bax and activate cas-
pase-3 expression, thus triggering striatal apoptotic mitochondria-dependent biochemi-
cal cascades. The first injection of METH (5 mg/kg, i.p.) produced a significant release
of DA that peaked 30 min and stayed above control levels up to 1.5 h within CPu. In
another set of experiments, rats were killed 1 and 24 h following the last injection, for
tissue DA and metabolite content measurement and Western blot analysis (24 h). Mul-
tiple doses induced DA depletion and increased turnover at both endpoints. Single-
dose METH reproduced these effects at 24 h; however, turnover was significantly
higher than that evoked by the multiple doses at 24 h. Although both paradigms
evoked similar DA depletion, however, none of the dosing regimens induced changes
in TH expression at 24 h. The former paradigm produced an increase in Bax expres-
sion in CPu not sufficient to induce cleavage of caspase-3 proenzyme at 24 h. This
study suggests that both paradigm induced changes in striatal dopaminergic markers
that are independent of terminal degeneration and striatal apoptotic mitochondria-de-
pendent caspase-3 driven cascade within 24 h. Synapse 60:185–193, 2006. Published
2006 Wiley-Liss, Inc.y
INTRODUCTION
Methamphetamine (METH) is a potent, indirect ac-
ting, sympathomimetic amine that is abused world-
wide by humans (Seiden and Sabol, 1996). Short- and
long-term health effects of METH use include stroke,
cardiac arrhythmia, anxiety, paranoia, hallucinations,
and structural changes to the brain (Anglin et al.,
2000). Acute METH intoxication might be due to an
increase in the levels of synaptic striatal dopamine
(DA) (Pereira et al., 2002, 2004), whereas long-term
effects could be secondary to persistent perturbations
in monoaminergic systems (Wagner et al., 1980).
METH-induced neurotoxicity in monoaminergic sys-
tems has been observed in rats given single large
doses (in the range of 20–100 mg/kg) (Cappon et al.,
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2000; Fukumura et al., 1998; Imam and Ali, 2001;
Seiden and Vosmer, 1984) or 5–10 mg/kg, given four
times at intervals of 2 h (Chapman et al., 2001). Toxi-
city in dopaminergic systems was also reported in
mice given either a single dose of METH (25 mg/kg)
(Hayashi et al., 2001) or multiple doses, with the ani-
mals receiving four injections of METH varying from
5 to 10 mg/kg at 2-h intervals (Ali et al., 1994; Fornai
et al., 2004; Thomas et al., 2004). Recently, in vivo
studies have suggested that METH can also cause
neuronal apoptosis in rodents by the concurrent acti-
vation of mitochondrial and endoplasmic reticulum
death pathways in mice striatal cells (Jayanthi et al.,
2004), and by the upregulation of Fas ligand/Fas
death pathway in rat striatal cells (Jayanthi et al.,
2005). An increasing number of proteins are impli-
cated in neuronal apoptosis mitochondria dependent,
including Bcl-2 family members Bax and the execu-
tioner caspase-3 (Mattson and Duan, 1999). There is
increasing evidence that exposure to METH is associ-
ated with caspases and proapoptotic Bcl-2 family
genes that are recruited during cell death (Itzhak and
Achat-Mendes, 2004). Bax exists in a stimulus-de-
pendent equilibrium between an inactive soluble cyto-
solic form and an active mitochondrial membrane-
associated or inserted form that induces cytochrome c
release and subsequent activation of execution phase
of apoptosis through triggering the activation of ter-
minal caspases such as caspase-3 (Benn and Woolf,
2004; Cao et al., 2001). Recent studies clearly pointed
out that Bax could trigger cell death through mecha-
nisms independent of the BH3 domain and independ-
ent of its interaction with Bcl-2 and Bcl-x-l (Eskes
et al., 1998; Jurgensmeier et al., 1998). Although the
majority of the earlier papers were concerned with
the long-term effects of the drug, the purpose of the
present study was to investigate the acute changes on
terminal dopaminergic toxicity markers, including DA
levels, DA turnover, and tyrosine hydroxylase (TH)
immunoreactivity in caudate-putamen (CPu) of adult
male Sprague-Dawley rats within 24 h following the
last injection using two METH-treatment paradigms.
Furthermore, the effects of the two METH treatments
on Bax immunoreactivity and caspase-3 cleavage in
CPu within 24 h were also evaluated.
MATERIALS AND METHODS
Animals and METH treatments
Adult male Sprague-Dawley rats (Charles River
Laboratories, Barcelona, Spain), weighing 250–380 g,
were housed two per cage under controlled environ-
mental conditions (12-h light/dark schedule, at room
temperature of 21 6 18C) with food and water sup-
plied ad libitum and subsequently housed individu-
ally after surgery or dosing. All experiments were
performed under the rules of the European Conven-
tion on Animal Care.
In the first set of experiments, rats were submitted
to in vivo microdialysis to test the effect of an injec-
tion of 5 mg/kg of METH on nigrostriatal dopaminer-
gic transmission. In a second set of experiments, ani-
mals were injected with either four injections of
METH (5 mg/kg, i.p. in a volume of 1.0 ml/kg) at 2-h
intervals or a single dose of METH (20 mg/kg, i.p. in
a volume of 1.0 ml/kg). Controls were injected with
saline (SAL).
Single-day METH dosing regimens could be a good
model of overdose in naive nontolerant abusers
(Davidson et al., 2005). The single-day single-dose
regimen was used to simplify the method of neurotox-
icity induction (Fukumara et al., 1998). All animals
survived these dosing regimens throughout the dura-
tion of the study, being killed by decapitation at ei-
ther 1 or 24 h following last injection. Brains were
quickly removed and CPu was dissected on ice and
stored at 808C. Unilateral CPu was used for DA and
DA metabolites’ tissue content measurement (1 and
24 h) and the contralateral hemisphere was used for
Western-blot analyses (24 h).
METH HCl was synthesized in the Organic Chem-
istry Department, University of Porto, Portugal.
METH HCl solutions were prepared in saline.
Surgery and in vivo microdialysis
Rats were anesthetized with sodium pentobarbital
and placed into a stereotaxic frame. The dorsal skull
was exposed and a small hole was drilled to allow im-
plantation of intracerebral guide cannula (CMA/12,
Carnegie Medicine, Sweden) into CPu (AP, þ0.5; Lat,
3; DV, 3). The cannula was fixed to the skull with
dental acrylic and two anchor screws. To avoid effects
of surgery and anesthesia, the dialysis experiments
were started 1 week after surgery. On the day of
tests, animals were hand held and a 4.0 3 0.5 mm2
dialysis probe (CMA/12) was slowly inserted through
the guide cannula into the CPu of awaken rats. The
animals were then placed in clear Plexiglas test
chambers and tethered to counterbalance arms that
allowed relatively free movement. The probes were
perfused at 1.3 ll/min with a microperfusion pump
(CMA/100) with artificial cerebrospinal fluid (ACSF)
containing (in mM): 140 NaCl, 2.4 KCl, 2.4 CaCl2, 1.0
MgCl2, 1.2 Na2HPO4, and 0.27 NaH2PO4, adjusted to
pH 7.2. Dialysate samples were collected in 30-min
intervals on ice and their DA and dihydroxyphenyl-
acetic acid (DOPAC) content was analyzed by high-
performance liquid chromatography (HPLC)-EC. A
minimum of two samples were taken to establish
baseline levels of extracellular DA and DOPAC before
drug administration (5 mg/kg METH, i.p. in a volume
of 1.0 ml/kg), which occurred 5 h following probe
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insertion. Controls were injected with SAL. After each
experiment, animals were killed and each probe track
was visualized.
Measurement of DA, DOPAC, and homovanillic
acid (HVA) by HPLC-EC
Extracellular levels of DA and DOPAC
Extracellular levels of DA and DOPAC were sepa-
rated on a reversed-phase Supelcosil LC-18 column
(4.6 mm; 7.5 cm; 3 lm particle size) with a mobile
phase (pH ¼ 3.0) consisting of 0.07 M KH2PO4, 2.85 mM
L-heptanesulfonic acid, 0.12 mM NaEDTA, and 7%
methanol (v/v). A flow rate of 1.2 ml/min was main-
tained and detection of the compounds achieved using
a glassy carbon working electrode set at 0.75 V. The
settings of sensitivity used were 0.05 and 0.5 nA/V for
DA and DOPAC, respectively. Thirty microliters were
injected onto the column.
Postmortem tissue content of DA,
DOPAC, and HVA
Animals were sacrificed by decapitation 1 and 24 h
following the last injection. The concentrations of DA,
DOPAC, and HVA were quantitated in CPu by a
modified HPLC method combined with electrochemi-
cal detection (Ali et al., 1994). Contents of DA,
DOPAC, and HVA were calculated as ng/mg of tissue
weight.
Western blot analyses
Animals were killed by decapitation 24 h following
the last injection. Western blotting was performed for
TH, Bax, and caspase-3. Each CPu was homogenized
in RIPA buffer (50 mM Tris  HCl, 150 mM NaCl, 1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS,
pH 7.5) containing protease inhibitor cocktail (Sigma,
St. Louis, MO), and samples were measured for pro-
tein concentration with BCA protein reagent (Pierce,
Rockford, IL). Equal amounts of protein (3 lg (TH
and Bax analysis) and 20 lg (caspase-3 analysis))
were loaded on each lane and the electrophoresis was
performed in a NOVEX XCell Sure Lock electrophore-
sis unit (Invitrogen Corp/NOVEX, Carlsbad, CA)
using NOVEX NuPage precast 10% Bis-Tris 15-lane
gels. Gels were transferred overnight to a polyvinyli-
dene difluoride (Invitrolon PVDF, Invitrogen Corp/
NOVEX) membrane and blocked with 5% nonfat dry
milk in Tris-buffered saline for 1 h. The blots were
probed with rabbit anti-TH (1:1000, Chemicon, Teme-
cula, CA), rabbit anti-Bax (1:500, Santa Cruz Biotech-
nology, Santa Cruz, CA), rabbit polyclonal caspase-3
(1:1000, BD PharMingen, San Diego, CA) for 2 h at
RT. To confirm equal protein loading and sample
transfer, blots were reprobed with mouse monoclonal
anti-a-tubulin (1:3000, Sigma; 2 h at room tempera-
ture). Immunoreactive bands were visualized by the
addition of horseradish peroxidase (HRP) conjugated
antibodies directed against rabbit and mouse IgG
(1:4000, Santa Cruz Biotechnology; 1:6000, Sigma) and
a highly sensitive enhanced chemiluminescent sub-
strate (SuperSignal1 West Dura Extended Duration
Substrate, Pierce). Analysis was performed using a
BioRad Chemi Doc XRS imaging system (Richmond,
CA) and densitometric analyses were performed using
the BioRad Quantity One. The relative density of each
band was normalized against that of a-tubulin.
Statistical analysis
Results were expressed as means 6 SEM. Micro-
dialysis data were converted to percent-of-baseline,
defined as the average of the last two values prior to
drug administration. Normalized Western blot data
were converted to percent-of-saline for each gel. This
approach normalizes differences in the development
of the chromagen solution between blots. Two to three
gels were run for each protein. Each blot contained
all experimental groups, allowing standardization ac-
ross all blots and these data were averaged. The dif-
ferences between groups were determined by ANOVA
followed by post hoc comparison (Bonferroni’s multi-
ple comparison test). Significant differences were de-
fined at P < 0.05.
RESULTS
In vivo microdialysis
DA baseline extracellular levels for SAL and METH
groups were pooled, being 15.5 6 1.7 pg/30 ll. Also,
there appeared to be no significant difference between
the DOPAC baseline levels from SAL and METH
groups (5.98 6 0.84 and 9.31 6 1.55 ng/30 ll, respec-
tively, P > 0.05).
The first injection of METH (5 mg/kg, i.p.) elicited a
14-fold increase in the extracellular DA levels 30 min
after dosing, and stayed significantly (P < 0.05) above
control levels up to 1.5 h within CPu (Fig. 1A). Dialy-
sate DOPAC levels showed a significant decrease that
peaked within 1 h and stayed significantly dec-
reased up to 2 h following METH treatment (Fig. 1B).
The extracellular levels of DA and DOPAC in the
SAL-treated animals stayed constant throughout the
experiment.
Caudate-putamen monoamine and metabolite
tissue content
The effects of multiple injections (4 3 5 mg/kg, i.p.)
and a single injection (20 mg/kg, i.p.) of METH on
CPu DA and its metabolites’ content were compared
and are shown in Figs 2A, 2B, and 2C). The effect of
both treatments on DA tissue content was significant
(P < 0.001). The multiple-dose regimen produced a
significant decrease (41%) in DA content in the CPu 1 h
187STRIATAL DOPAMINERGIC MARKERS AND APOPTOSIS
Synapse DOI 10.1002/syn
after the last injection. Twenty-four hours following
last METH injection, CPu DA remained depleted
(54%). On the other hand, the single-dose regimen of
METH had no significant effect on DA levels 1 h fol-
lowing treatment. In contrast, 24 h following single
METH injection, CPu DA was significantly reduced
compared with that of SAL-treated animals (68%).
Fig. 1. Effects of METH on extracellular levels of DA (A) and
DOPAC (B) in caudate-putamen (CPu). Extracellular levels of DA
and DOPAC were measured in CPu from adult male SD rats by
in vivo microdialysis following a single injection of METH (5 mg/kg,
i.p.; METH5) or saline (SAL) at the time point indicated by the
arrow. Each value is presented as mean 6 SEM (n ¼ 4 for SAL and
n ¼ 7 for METH5).
Fig. 2. Effects of METH on DA (A), DOPAC (B), and HVA (C)
contents in CPu. Multiple injections of METH (4 3 5 mg/kg, i.p. at
2-h intervals; 4 3 METH5) or a single injection of METH (20 mg/
kg, i.p.; METH20) was administered to adult, male SD rats. Ani-
mals were sacrificed at 1 and 24 h following treatment. Each value
is presented as mean 6 SEM (n ¼ 4–5). A: *P < 0.001 compared
with saline group (SAL); #P < 0.05, ##P < 0.001 compared to
METH20 at 1-h group. B: *P < 0.05 compared with saline group
(SAL); #P < 0.05 compared with METH20 at 24-h group.
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DA depletion induced by both treatments 24 h follow-
ing the last injection was not significantly different
from each other. However, simultaneous measure-
ment of DOPAC and HVA contents in the CPu (Figs.
2B and 2C) did not show any significant alterations
except for the single METH injection that increased
DOPAC tissue levels at 24 h (175% of control, P <
0.05). Finally, both treatments induced significant
alterations (P < 0.001) in DA turnover ((DOPAC þ
HVA)/DA) (Fig. 3). The multiple-dose regimen pro-
duced a similar increase in DA turnover in CPu at
both endpoints (240 and 285% of control, P < 0.05).
The single-dose regimen of METH had no significant
effect on DA turnover 1 h following treatment. How-
ever, this regimen induced a robust increase (681% of
control; P < 0.001) in DA turnover 24 h following
METH injection. Moreover, the increment in DA turn-
over 24 h following single-dose regimen of METH was
significantly higher than the one induced by the mul-
tiple-dose regimen (P < 0.05).
Caudate-putamen TH expression
Results from the densitometric quantitation of West-
ern blots of CPu TH are shown in Figure 4. No signifi-
cant changes were observed in TH expression in any of
the dosing regimens 24 h following METH treatment.
Caudate-putamen apoptotic
proteins expression
There is scarce information on the damaging effect
of METH on neurons postsynaptic to the DA termi-
nals. To this end, we studied the expression of the ap-
optotic regulator protein Bax and the cleavage of the
executioner caspase-3 under METH effect. Results
from the densitometric quantitation of Western blots
of CPu Bax are shown in Figure 5. Only the multiple
injection of METH produced a significant (P < 0.05),
although modest, increase in Bax expression in CPu
24 h following METH treatment (Fig. 5). However, no
significant changes were observed in cleavage of the
caspase-3 proenzyme (32 kDa) 24 h following METH
treatment (Fig. 6).
DISCUSSION
This study showed that although both METH
administration paradigms induced a significant loss
of DA, with increased DA turnover in the rat CPu
24 h after treatment, however, similar dosing neither
changed TH immunoreactivity nor cleaved pro-cas-
pase-3. Typically, rodent methamphetamine research
uses a single-day regimen of multiple 5–10 mg/kg i.p.
injections, which result in loss of DA content in the
early withdrawal period and eventually neurotoxicity
(Davidson et al., 2005). In the present study, we used
both multiple injections of METH (4 3 5 mg/kg, i.p.)
at 2-h intervals and a single injection of METH (20
mg/kg, i.p.) to further evaluate the impact of METH
Fig. 4. Effects of METH on CPu TH expression as revealed by
Western blot analysis. Multiple injections of METH (4 3 METH5)
or a single injection of METH (METH20) was administered to adult,
male SD rats. Animals were sacrificed at 24 h following treatment.
The bands shown represent the 62-kDA TH and the 50-kDA a-tubu-
lin. Bands are taken from the same blot and are representative of
three different experiments with similar results. The density of TH
band/a-tubulin band determines the relative quantity of TH in each
sample. Data are expressed as percentages of the control (SAL) and
are presented as means 6 SEM (n ¼ 4 animals per group).
Fig. 3. Effects of METH on DA turnover ([(DOPAC þ HVA)/DA])
in CPu. Multiple injections of METH (4 3 METH5) or a single injec-
tion of METH (METH20) was administered to adult, male SD rats.
Animals were sacrificed at 1 and 24 h following treatment. Each
value is presented as mean 6 SEM (n ¼ 4–5). *P < 0.05, **P <
0.001 compared with saline group (SAL); #P < 0.05, ##P < 0.001
compared with METH20 at 24-h group.
189STRIATAL DOPAMINERGIC MARKERS AND APOPTOSIS
Synapse DOI 10.1002/syn
on terminal dopaminergic toxicity markers, including
DA levels, DA turnover, and TH immunoreactivity in
CPu of rats within 24 h. Single-dose regimens may
aid in uncovering the as yet unknown mechanisms of
substituted amphetamine neurotoxicity, because they
reduce the inherent complexity present in repeated
dosage regimens (Miller and O’Callaghan, 2003). It is
noteworthy that these METH doses are within the
range of doses that are taken by human bingers
(Davidson et al., 2005). We chose the time frame in
which damage to DA nerve terminals is considered to
be initiating and amplifying. For example, METH
was shown to cause a significant increase in micro-
glial activation, implicated in many forms of neuronal
damage and disease 24–48 h after treatment (Thomas
et al., 2004).
Most of the METH-induced neurotoxicity litera-
tures have revolved around increased DA outflow
(Cadet and Brannock, 1998). In the present study, it
is shown that the first injection of METH (5 mg/kg,
i.p.) produced a robust output of DA to about 14-fold
above basal levels that stayed significantly above con-
trol levels up to 1.5 h within CPu. In recent studies,
we showed that higher METH concentrations (10 and
20 mg/kg, i.p.) evoked about 20-fold increase in
extracellular levels (Pereira et al., 2002, 2004). The
main difference between the present and the former
studies would be the duration of the dopaminergic
signal: transient (5 mg/kg METH) vs. sustained
(higher METH concentrations). Dopaminergic trans-
mission is highly regulated presynaptically by auto-
and heteroreceptors and DA transporters (DATs). The
mutual interaction between receptors and DATs pro-
vides a complex regulatory system that shapes the
DA signal (see Schmitz et al., 2003 for a recent
review). Therefore, the interference of higher doses of
METH with this regulation is apparently more impor-
tant than the one exerted by 5 mg/kg METH. In addi-
tion, METH also inhibits DA uptake and intraneuro-
nal oxidative metabolism of DA through MAO in-
hibition (Jones et al., 1998; Metzger et al., 2000).
Accordingly, dialysate DOPAC levels showed a signifi-
cant decrease that peaked within 1 h and stayed
significantly decreased up to 2 h following 5 mg/kg
METH treatment. As most of striatal DA measured in
postmortem tissue is intracellular rather than synap-
tic, our finding of tissue concentrations of DA sug-
gests that both METH treatments lead to depletion of
tissue stores in rat at 24 h. It is noteworthy that DA
depletion induced by both treatments was not signifi-
cantly different. DA depletion from striatum faithfully
reflects other measures of DA nerve ending damage
caused by METH, such as reduced TH immunoreac-
tivity (Thomas et al., 2004). However, none of the dosing
regimens induced changes in TH expression at 24 h.
Striatal TH immunoreactivity is one of the markers
used to assess the integrity of dopaminergic termi-
nals. Therefore, our data suggest that DA depletion
does not correspond to terminal degeneration within
Fig. 6. Effects of METH on CPu caspase-3 cleavage as revealed
by Western blot analysis. Multiple injections of METH (4 3
METH5) or a single injection of METH (METH20) was administered
to adult, male SD rats. Animals were sacrificed at 24 h following
treatment. The bands shown represent the 32-kDA pro-caspase 3
and the 50-kDA a-tubulin. Bands are taken from the same blot and
are representative of two different experiments with similar results.
Each group comprises four animals.
Fig. 5. Effects of METH on CPu Bax expression as revealed by
Western blot analysis. Multiple injections of METH (4 3 METH5)
or a single injection of METH (METH20) was administered to adult,
male SD rats. Animals were sacrificed at 24 h following treatment.
The bands shown represent the 23-kDA Bax and the 50-kDA a-
tubulin. Bands are taken from the same blot and are representative
of three different experiments with similar results. The density of
Bax band/a-tubulin band determines the relative quantity of Bax in
each sample. Data are expressed as percentages of the control (SAL)
and are presented as means 6 SEM (n ¼ 4 animals per group). *P
< 0.05 compared with control group (SAL); #P < 0.05, compared
with METH20 group.
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this time frame. This is consistent with chronic expo-
sure to METH inducing reduced striatal DA levels
without causing permanent degeneration of striatal
DA nerve terminals in young human subjects (Wilson
et al., 1996). This DA depletion could reflect, instead,
a compensatory downregulation of DA biosynthesis in
response to prolonged dopaminergic stimulation
caused by METH (Wilson et al., 1996). Interestingly,
Wang et al. (2004, 2005) showed similar results with
MDMA inducing 5-HT depletion, independent of ter-
minal degeneration. Alternatively, Wang et al. (2004)
showed that 7.5 mg/kg METH (four times at 2-h
intervals) induced a decrease in TH immunoreactivity
in rat CPu at 24 h. The dosing regimen and the tech-
nique used to measure TH immunoreactivity by this
group are different from those used in our study.
Therefore, caution should be taken while drawing a
comparison between studies. However, our data does
not rule out the possibility that METH treatment
could induce TH depletion at later time points. In
fact, Fukumara et al. (1998) found that a single dose
of 20 mg/kg METH reduced TH immunoreactivity 3
days posttreatment. Also, Zhu et al. (2005) demon-
strated that using a single bolus of METH (30 mg/kg)
does not cause depletion of TH at 16 or 24 h, but
induced TH depletion at 2 days, reaching the lowest
point 3 days after exposure. These might suggest that
down-regulation of TH and other events at the DA ter-
minals (e.g., inhibition of vesicular DA uptake (Brown
et al., 2000)) must precede the depletion of TH.
Increased DA turnover after METH treatment, and
thus the potential for increased oxidative stress, is
also widely used as an index of METH-induced toxic-
ity to DA nerve endings. The DA turnover increase
shown in the present study may reflect the combina-
tion of two factors: (1) DA depletion and (2) an
increase in intraneuronal oxidative metabolism of DA
through MAO, as indicated by either no changes or
an increase in DOPAC tissue content (multiple and
single injection, respectively). Taking into considera-
tion that increased turnover elicited by single dose of
METH was significantly higher than that evoked by
the multiple doses at 24 h, this suggests that single
injection is more important to dopaminergic terminals
than the multiple-injection paradigm. This might be
due to pharmacodynamics of a bulk injection of 20
mg/kg rather than 4 3 5 mg/kg of METH. Cohen
(1984) pointed out that conditions that increase turn-
over of DA might also increase the formation of reac-
tive oxygen species. Consistently, Pereira et al. (2004)
showed that 10 mg/kg METH evoked a delayed OH
formation in rat CPu when compared with the fast
DA peak. Drug-induced oxidative stress is an attrac-
tive construct that can account for many of the effects
of METH on the DA nerve endings, such as inhibition
of TH activity (Haughey et al., 1999). It could also be
an early event that would eventually lead to METH-
induced apoptosis (Cadet et al., 2003). Recent animal
studies have suggested that in addition to the in-
volvement of pro-death genes of the Bcl-2 family
(Bax), AMPH and METH toxicity are associated with
increases in caspase-3 activity in striatal postsynaptic
neurons (Cadet et al., 2003; Jayanthi et al., 2004;
Krasnova et al., 2005). The present work also aimed
to evaluate whether the typical neurotoxic regimen
(4 3 5 mg/kg METH, i.p.; at 2-h intervals) and the
single METH injection (20 mg/kg, i.p.) would also change
Bax and activate caspase-3 expression, thus trigger-
ing striatal apoptotic mitochondria-dependent bio-
chemical cascades in rat CPu 24 h posttreatment.
Again, it is important to assess early time points be-
cause cells undergoing apoptosis might be removed
by endogenous phagocytes and microglia, before the
damaged cells can lyse and spill their contents into
surrounding areas (Deng et al., 1999). Only the multi-
ple-injection paradigm produced an increase in Bax
expression in Cpu, although not sufficient to induce
cleavage of the caspase-3 proenzyme at 24 h. This is
the first study to show an increase in Bax expression
in rat striatal cells in vivo induced by METH. Our ob-
servation is in line with METH inducing overexpres-
sion of Bax in an immortalized cell line (Deng et al.,
2002). The lack of activation of caspase-3 is not sur-
prising, considering that Bowyer et al. (1994) did not
find any evidence of cell death in rat striatum follow-
ing 4 3 5 mg/kg METH treatment. On the contrary,
Jayanthi et al. (2004, 2005) showed that 40 mg/kg
METH induced cleavage of pro-caspase-3 peaking
between 8 and 24 h in mice striatum and caspase-3 acti-
vation at 24 h in rat striatum. However, it should be
pointed out that in these studies, the doses of METH
used were twice as much as was used in our study.
Finally, one should not neglect the hypothesis that
there could be apoptotic processes that progress inde-
pendent of caspase activity and that may possibly be
mediated by release of the apoptosis inducing factor
(AIF) from mitochondria and their translocation to
the nucleus (Chu et al., 2005; Cregan et al. 2002; Joza
et al. 2001). Interestingly, Jayanthi et al. (2004)
reported that the release of AIF from mitochondria
was detected 30 min after 40 mg/kg METH injection
and in the nuclear fraction 4 h thereafter in mouse
striatum.
As demonstrated in the present study, METH has
greater impact on the presynaptic terminals than it
does on the postsynaptic neurons, suggesting that
presynaptic terminals are subjected to more damag-
ing influences or that the nigrostriatal pathway is
more vulnerable to toxic injury. We further suggest
that METH-induced dopaminergic neurotoxicity, as
seen by DA depletion and increased DA turnover, may
occur independently of terminal degeneration. Bowyer
et al. (1992, 1994) reported that METH-induced termi-
nal degeneration generally occurs only with the use of
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regimens producing a lethal hyperthermia (418C)
that often requires an ‘‘ice-bath rescue.’’ In the present
study, all animals survived the dosing regimens. How-
ever, we did not measure body temperature, and there
is a possibility that we had some transient hyperther-
mia that was not lethal. It is possible that alternative
mechanisms, besides axonal degeneration, are opera-
tional in decreasing dopaminergic phenotypic markers
in the METH-exposed brain, as was suggested by Gui-
larte et al. (2003). It is also proposed that METH-
induced striatal neurotoxicity is not dependent on mi-
tochondria-driven apoptotic cascades through caspase-
3 activation. The extent of neurotoxicity to striatal
postsynaptic neurons might be dependent upon several
factors including: (a) animal species, (b) dosage and
frequency of drug administration, (c) the ambient tem-
perature during drug administration, (d) thermoregu-
lation, and (e) seizures. This study further stresses
that the use of a single dose model proves to be a valu-
able tool to further understand the mechanisms un-
derlying METH-induced nigrostriatal dopaminergic
neurotoxicity.
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